CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is pleased to announce a suite of comprehensive mRNA-LNP Vaccine Laboratory Process Development Assays. This latest addition to CD Bioparticles' extensive service portfolio is specifically designed for the rapid and efficient development of mRNA-LNP vaccines.
The mRNA molecule is well known to...
The MRNA Vaccine and Therapeutics Market in 2023 is US$ 46.83 billion, and is expected to reach US$ 164.67 billion by 2031 at a CAGR of 17.02%.
FutureWise Research published a report that analyzes MRNA Vaccine and Therapeutics Market trends to predict the market's growth. The report begins with a description of the business environment and explains the commercial summary of the chain structure....
The continued emergence of SARS-CoV-2 variants and breakthrough infections following vaccination underscore the need to study the effectiveness of current COVID-19 vaccines in the real world.
To date, only two mRNA COVID-19 vaccines have been approved for marketing, mRNA-1273 developed by Moderna and BNT162b2 developed by Pfizer/BioNTech, which have proven to be very effective in...
The “mRNA Therapeutics and Vaccines Market: Industry Trends and Global Forecasts, 2022 – 2035” report features an extensive study of the current market landscape and the likely future potential associated with the biopharmaceutical contract manufacturing market, over the next decade.
The study also includes an elaborate discussion on the future potential of this...